Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).
• Patients aged 19 years old
• Patients with AF and CHA2DS2-VA score ≥2.
• ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)
‣ STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12
⁃ NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12
• Symptoms of ischemia.
∙ New or presumed new significant ST-T wave changes
∙ Development of pathological Q waves on electrocardiography.
∙ Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.
∙ Intracoronary thrombus detected on angiography.
• Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.